Management of Oropharyngeal Cancer
2016 AAO-HNSF Annual Meeting &OTO EXPOSM
Keyword(s)
oropharyngeal cancer, chemoradiation protocols, role of HPV
The optimal management of oropharyngeal cancer remains an evolving and often contentious topic. Historically, the gold standard for treatment of oropharyngeal malignancy is surgery. However, over the years this has shifted to chemoradiation protocols based on data extrapolated from randomized clinical traials of advanced laryngeal cancer. Recently, advances in transoral techniques (laser and robotic resection) have greatly faciliated surgical treatment of these lesions with comparable oncologic outcome and equal, if not improved, functional outcome. This course will provide a history of the management of oropharyngeal cancer. It will present when surgical and non-surgical approaches are warrented and the rapidly expanding use of transoral resection. Contemporary outcome data will be reviewed and controversial cases will be presented.
Description
The optimal management of oropharyngeal cancer remains an evolving and often contentious topic. Historically, the gold standard for treatment of oropharyngeal malignancy is surgery. However, over the years this has shifted to chemoradiation protocols based on data extrapolated from randomized clinical traials of advanced laryngeal cancer. Recently, advances in transoral techniques (laser and robotic resection) have greatly faciliated surgical treatment of these lesions with comparable oncologic outcome and equal, if not improved, functional outcome. This course will provide a history of the management of oropharyngeal cancer. It will present when surgical and non-surgical approaches are warrented and the rapidly expanding use of transoral resection. Contemporary outcome data will be reviewed and controversial cases will be presented. Learning Objectives:1: Understand the basic treatment paradigms for oropharyngeal malignancy. 2: Understand the advantages and disadvantages of an upfront surgical approach versus non-surgical approach. 3: Appreciate the role of HPV in the management of patients with oropharyngeal cancer.Faculty:Jeremy Richmon, MD (No relationships to disclose), Derrick T. Lin, MD (No relationships to disclose), Harry Quon, MD (No relationships to disclose), MS, Ezra Cohen, MD (AstraZeneca: Consultant/Advisory Board; Bristol-Meyers Squibb: Consultant/Advisory Board; Human Longevity, Inc.: Consulting Fees (e.g., advisory boards); Merck: Consultant/Advisory Board; Merck Serono: Consultant/Advisory Board; Pfizer: Consultant/Advisory Board).
